Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | ALB | P02768 | 11/20 | 0.53 |
| ▸ | IL2 | P60568 | 11/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | DDO | Q99489 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14765166 | 0.84 | KDM4E (0.58) | HRH4FLT3ALBIL2DAO | |
| SCHEMBL24019693 | 0.84 | ALB (0.60) | HRH4FLT3ALBIL2DAO | |
| SCHEMBL30147598 | 0.83 | FLT3 (0.55) | FLT3DAODDOALOX15 | |
| SCHEMBL16234660 | 0.82 | HRH4 (0.59) | HRH4FLT3ALBIL2DAO | |
| SCHEMBL3417091 | 0.82 | FLT3 (0.60) | HRH4FLT3ALBIL2DAO | |
| SCHEMBL30189206 | 0.82 | FLT3 (0.60) | HRH4FLT3ALBIL2DAO | |
| SCHEMBL19476401 | 0.81 | FLT3 (0.51) | HRH4FLT3ALBIL2DAO | |
| SCHEMBL30147671 | 0.81 | ALOX15 (0.50) | HRH4FLT3ALOX15GAA | |
| SCHEMBL31414534 | 0.81 | HRH4 (0.56) | HRH4FLT3HDAC3HDAC1ALOX15 | |
| SCHEMBL2323348 | 0.81 | FLT3 (0.59) | HRH4FLT3ALBIL2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| CN-115551864-A | Substituted tricyclic amides, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | HRH4 1673/4885FLT3 1327/4885ALB 1081/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | HRH4 2842/4885FLT3 1881/4885ALB 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.